Clinical trials: Chronic Hypertension
Glaucoma, Ocular Hypertension
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
The purpose of this study is to evaluate how tolerable, safe, and effective it is to give INO-8875 eye drops to adults with glaucoma or ocular hypertension.
- Trial name
- NCT01123785
- Testing
- INO-8875
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Pulmonary Arterial Hypertension
Tezosentan in Pulmonary Arterial Hypertension
Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial…
- Trial name
- NCT01077297
- Testing
- Tezosentan
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 3 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Chronic Liver Disease, Cirrhosis
MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy
The purpose of this study is to determine the effect on the (carbon 13 labelled(13C)-Methacetin Breath Test (MBT) of i.v. propranolol, a non-selective beta blocker (NSBB) following initial administration and after chronic use of…
- Conditions
- Chronic Liver Disease, Cirrhosis, Esophageal Varices, Portal Hypertension
- Trial name
- NCT01851252
- Testing
- Methacetin (with Breath testing device)
- Where
- Israel
- Volunteers
- 19 people
- Sponsor
- Meridian Bioscience, Inc.
Hypertension
Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.
It is hypothesised that ambrisentan may provide benefit to subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), where currently no proven or licensed treatment options exist.
- Trial name
- AMBER I (NCT01884675)
- Testing
- Ambrisentan 5 mg
- Where
- 51 sites in United States, Argentina and 14 more
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Hypertension, Chronic Heart Failure
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
The purpose of this study is to assess the tolerability of BIA 5-453 after six multiple rising dose regimens of BIA 5-453.
- Trial name
- NCT02840565
- Testing
- BIA 5-453
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Hypertension
Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension
The primary objective of this trial was to assess the efficacy and safety of telmisartan 80 mg during open-label, long-term treatment.
- Trial name
- NCT02177422
- Testing
- Telmisartan, Hydrochlorothiazide
- Volunteers
- 489 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Failure
Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD
The aim of this study is to assess the superiority of the new low sodium peritoneal dialysis (PD) solution PDsol 12 in comparison with a conventional, already marketed solution, Gambrosol trio 40, in the treatment of the…
- Trial name
- PDOne (NCT00794326)
- Testing
- Solution for Peritoneal Dialysis
- Where
- 29 sites in Denmark, France and 3 more
- Volunteers
- 140 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Hypertension, Pulmonary, Pulmonary Disease, Chronic Obstructive
Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of a single oral dose of BAY63-2521 in patients with pulmonary hypertension due to chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00640315
- Testing
- Riociguat (Adempas, BAY63-2521) 1.0 mg, Riociguat (Adempas, BAY63-2521) 2.5 mg
- Where
- 7 sites in Germany
- Volunteers
- 23 people
- Sponsor
- Bayer
Glaucoma
A Prospective, Multicenter, Open-label, Safety and Preliminary Efficacy Study of the Surgical Implantation of OPKO's Glaucoma Drainage Device (AquashuntTM) in Patients With Refractory Chronic Forms of Open Angle Glaucoma (OAG)
A prospective, multicenter, open-label, safety and preliminary efficacy study of the surgical implantation of OPKO's glaucoma drainage device (AquashuntTM) in patients with refractory chronic forms of open angle glaucoma (OAG).
- Trial name
- NCT00834223
- Testing
- Aquashunt
- Where
- Dominican Republic
- Volunteers
- 15 people
- Sponsor
- OPKO Health, Inc.
Chronic Thromboembolic Pulmonary Hypertension
Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension
The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH), to patients suffering from inoperable chronic thromboembolic…
- Trial name
- NCT00313222
- Testing
- bosentan
- Volunteers
- 157 people
- Sponsor
- Actelion
Hypertension
Clinical Trial to Evaluate Pharmacokinetic Profiles and Safety Between CKD-385 and D935 in Healthy Volunteers
A randomized, open-label, fed, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-385 in healthy volunteers
- Trial name
- NCT03748212
- Testing
- D935 Cap. 1T, CKD-385 Tab. 1T
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Viral Hepatitis B, Viral Hepatitis D
Replicor Compassionate Access Program
The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to…
- Conditions
- Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis
- Trial name
- RCAP (NCT05683548)
- Testing
- REP 2139-Mg, Tenofovir Disoproxil Fumarate, Pegylated interferon alpha2a
- Where
- 13 sites in Austria, France and 3 more
- Sponsor
- Replicor Inc.
Rate of CKD Diagnosis in Patients With AH and CKD Markers, Demographic and Clinical Characteristics for Those Patients
Prospective Observational Multicenter Study of Patients With AH and CKD Markers in Kazakhstan (PROGRESS-CKD)
Multicenter, non-interventional PRospective Observational study with retrospective analysis to describe the rate of CKD diaGnosis in patients with aRtErial hypErtenSion and CKD markerS in Kazakhstan
- Conditions
- Rate of CKD Diagnosis in Patients With AH and CKD Markers, Demographic and Clinical Characteristics for Those Patients, Routine Therapy Before and After the Diagnosis of CKD
- Trial name
- D1843R00359 (NCT06744335)
- Where
- 28 sites in Kazakhstan
- Volunteers
- 1,283 people
- Sponsor
- AstraZeneca
Sleep Apnea, Asthma
Sleepiz One+ vs. Capnography and Electrocardiography
Respiratory Rate (RR) and heart rate (HR) are vital signs crucial for assessing a patient's overall health, providing insights into various conditions and stressors.
- Conditions
- Sleep Apnea, Asthma, COPD, Hypertension
- Trial name
- NCT06569940
- Testing
- Sleepiz One+
- Where
- Switzerland
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sleepiz AG
Hypertension
Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study
Chronic kidney disease (CKD) and hypertension are two closely related common chronic diseases that have serious implications to human health.
- Trial name
- ADRENAL (NCT03194633)
- Testing
- Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)
- Where
- China
- Volunteers
- 871 people
- Sponsor
- Bayer
Open-Angle Glaucoma
Memantine in Patients With Chronic Glaucoma
Randomized double-masked clinical trial of memantine in patients with glaucoma
- Trial name
- NCT00141882
- Testing
- memantine
- Volunteers
- 1,119 people
- Sponsor
- Allergan
Hypertension, Pulmonary
The Effect of Tracleer® on Male Fertility
The objective of the study is to evaluate the effects of chronic TRACLEER® treatment on testicular function via semen analysis in male patients with primary pulmonary arterial hypertension (PAH).
- Trial name
- NCT00082186
- Testing
- bosentan
- Volunteers
- 22 people
- Sponsor
- Actelion
Cardiac Decompensation
Evaluate Heart Failure Patients With Specially Designed Patient Adherence and Monitoring Software on Standard Mobile Devices
This is planned as a feasibility study. The objective is to evaluate a specially designed patient adherence and monitoring software on standard mobile devices in remote monitoring of heart failure patients.
- Trial name
- REMOTE-HF-1 (NCT01430936)
- Where
- 5 sites in United States, India and 1 more
- Volunteers
- 51 people
- Sponsor
- Aventyn, Inc.
Hypertension
Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension
The purpose of this extension study is to compare the long-term safety of valsartan versus enalapril, and the effectiveness of the combination of valsartan and enalapril versus enalapril alone in children with hypertension.
- Trial name
- NCT00446511
- Testing
- Valsartan, Enalapril
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 250 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease
Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.
Researchers in this study want to learn more about the safety of the drug runcaciguat and how well it works when given at the highest dose as tolerated by the individual patient whose kidneys are not working properly and…
- Trial name
- CONCORD (NCT04507061)
- Testing
- runcaciguat
- Where
- 71 sites in Austria, Belgium and 11 more
- Volunteers
- 243 people
- Sponsor
- Bayer